CHAPTER 7 Methods for detection of HPV infection and its clinical utility

International Journal of Gynecology and Obstetrics

Volumn 94, Issue SUPPL. 1, 2006, Pages

  Villa, Luisa Lina ^a   Denny, Lynette ^a  

^a NONE

Author keywords

Cervical cancer; Human papillomavirus testing; Polymerase chain reaction

Indexed keywords

VIRUS DNA;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; MOLECULAR BIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERODIAGNOSIS; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

EID: 33846632806     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(07)60013-7     Document Type: Article

References (41)

1. Iftner T., and Villa L. Chapter 12: Human papillomavirus technologies. J Natl Cancer Inst Mono 31 (2003) 80-88
2. Nuovo G., Moritz J., Walsh L., MacConnell P., and Koulos J. Predictive value of human papillomavirus DMA detection by filter hybridization and Polymerase Chain Reaction in women with negative results of colposcopic examination. Anatom Pathol 98 5 (1992) 489-492
3. Stoler M., Wolinsky S., Whitbeck A., Broker T., and Chow L. Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with Message-Specific RNA probes. Virology 172 (1997) 331-340
4. Begum S., Gillison M., Ansari-Lari M., Shah K., and Westra W. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9 (2003) 6469-6475
5. Lorincz A., and Anthony J. Advances in HPV detection by hybrid capture [letter]. Papillomavirus Rep 145 (2001) 54-58
6. Gravitt P., and Jamshidi R. Diagnosis and management of oncogenic cervical human papillomavirus infection. Infect Dis Clin North Am 19 2 (2005) 439-458
7. Jacobs M., Snijders P., Voorhorst F., Dillner J., Forslund O., Johansson B., et al. Reliable high risk HPV DMA testing by polymerase chain reaction: an intermethod and intram-ethod comparison. J Clin Pathol 52 7 (1999) 498-503
8. Kleter B., van Doom L., Schrauwen L., Molijn A., Sastrowijoto S., ter Schegget J., et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37 (1999) 2508-2517
9. Gravitt P., Burk R., Lorincz A., Herrero R., Hildesheim A., Sherman M., et al. A comparison between Real-Time Polymerase and Hybrid Capture 2 for human papillo-mavirus DMA quantitation. Cancer Epidemiol Biom Prev 12 (2003) 477-484
10. Schlecht N., Trevisan A., Duarte-Franco E., Rohan T., Ferenczy A., Villa L., et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 103 (2003) 519-524
11. Van Duin M., Snijders P., Schrijnemakers H., Voorhorst F., Rozendaal L., Nobbenhuis M., et al. Human papillo-mavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN ll/lll and viral clearance. Int J Cancer 98 (2002) 590-595
12. Molden T., Kraus I., Skomedal H., Nygard J., and Hagmar B. Comparison of Human Papillomavirus messenger RNA and DMA detection: a cross-sectional study of 4,136 women >30years of age with a 2-year follow-up of high-grade squa-mous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 14 2 (2005) 367-373
13. Klaes R., Woerner S., Ridder R., Wentzensen N., Duerst M., Schneider A., et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 59 24 (1999) 6312-6316
14. Quint W., Pagliusi S., Lelie N., de Villiers E., and Wheeler C. Results of the first world health organization international collaborative study of detection of human papillomavirus DMA. J Clin Microbiol 44 2 (2006) 571-579
15. Snijders P., van den Brule A., and Meijer C. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 201 1 (2003) 1-6
16. Ho G., Bierman R., Beaqrdsley L., Chang C., and Burk R. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 (1998) 423-428
17. Wheeler C., Greer C., Becker T., Hunt W., Anderson S., and Manos M. Short-term fluctuations in the detection of cervical human papillomavirus DMA. Obstet Gynecol 88 (1996) 261-268
18. Hildesheim A., Schiffman M., Gravitt P., Glass A., Greer C., Zhang T., et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 169 (1994) 235-240
19. Evander M., Edlund K., Gustafsson A., Jonsson M., Karlsson R., Rylander E., et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 171 (1995) 1026-1030
20. Moscicki A., Palefsky J., Smith G., Siboshski S., and Schoolnik G. Variability of human papillomavirus DMA testing in a longitudinal cohort of young women. Obstet Gynecol 82 (1993) 578-585
21. Koutsky L., Holmes K., Critchlow C., et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327 18 (1992) 1272-1278
22. Salmeron J., Lazcano-Ponce E., Lorincz A., et al. Comparison of HPV-based assays with Papanicoloau smears for cervical cancer screening in Morelos State Mexico. Cancer Causes Control 14 6 (2003) 505-512
23. Schiffman M., Herrero R., Hildesheim A., Sherman M., Bratti M., Wacholder S., et al. HPV DMA testing in cervical cancer screening: results from a high-risk province in Costa Rica. JAMA 283 (2000) 87-93
24. Kuhn L., Denny L., Pollack A., and Wright T. Human papillomavirus DMA testing for cervical cancer screening in lowresource settings. J Natl Cancer Inst 92 (2000) 818-825
25. Petry K., Menton S., Menton M., van Loenen-Frosch F., de Carvalho Gomes H., Holz B., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8468 patients. Br J Cancer 88 (2003) 1570-1577
26. Franco E. Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monog 31 (2003) 89-96
27. Sherman M., Lorincz A., Scott D., Wacholder S., Castle P., Glass A., et al. Baseline cytology human papillomavirus testing and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95 (2003) 46-52
28. Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362 (2003) 1871-1876
29. Lynette D., Louise K., Lili R., Ralph M.R., Amy P., Attila L., et al. Two-stage cervical cancer screening: an alternative for resource-poor settings. Am J Obstet Gynecol 183 (2000) 383-388
30. Castle S., Wacholder S., Sherman M., Lorincz A., Glass A., Scott D., et al. Absolute risk of a subsequent abnormal Pap among oncogenic human papillomavirus DMA-positive cytologically negative women. Cancer 95 (2002) 2145-2151
31. Wright Jr. T., Denny L., Kuhn L., Pollack A., and Lorincz A. HPV DMA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 283 (2000) 81-86
32. Belinson J., Qiao Y., Pretorius R., Zhang W., Rong S., Huang M., et al. Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int J Gynecol Cancer 13 (2003) 819-826
33. Schiffman M., and Adrianza M. ASCUS-LSIL Triage Study. Design methods and characteristics of trial participants. Acta Cytol 124 (2000) 203-211
34. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomised trial. J Natl Cancer Inst 92 5 (2000) 397-402
35. Wright Jr. T., Schiffman M., Solomon D., Cox J., Garcia F., Goldie S., et al. Interim Guidance for the use of Human Papillomavirus DMA Testing as an Adjunct to Cervical Cytology for Screening. Obstet Gynecol 103 (2004) 304-309
36. Wright Jr. T., Cox J., Massad L., Twiggs L., Wilkinson E., and ASCCP-Sponsored Consensus Conference. Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287 (2002) 2120-2129
37. Mitchell M., Tortolero-Luna G., Cook E., Whittaker L., Rhodes-Morris H., and Silva E. A randomised clinical trial of cryotherapy laser vaporisation and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 92 (1998) 737-744
38. Soutter W., de Barros Lopes A., Fletcher A., Monaghan J., Duncan I., and Paraskevaidis E. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 349 (1997) 978-980
39. Lorincz A. Screening for cervical cancer: new alternatives and research. Salud Publica Mex 45 suppl 3 (2003) S376-S387
40. Paraskevaidis E., Koliopoulos G., Alamanos Y., Malamou-Mitsi V., Lolis E., and Kitchener H. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol 98 (2001) 833-836
41. Paraskevaidis E., Arbyn M., Sotiriadis A., Diakomanolis E., Martin-Hirsch P., and Koliopoulos G. The role of HPV DMA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 30 (2004) 205-211